01 Increasing Shift toward High-resolution Antigen Profiling ExpansionA key blood transfusion diagnostics market trend is the expansion of high-resolution antigen profiling. High-resolution antigen profiling refers to the growing use of molecular genotyping techniques to identify a broad spectrum of red blood cell antigens beyond traditional ABO and Rh typing. This includes extended systems such as Kell, Duffy, Kidd, MNS, and Lutheran, enabling precise donor-recipient compatibility matching. Reducing reliance on serological testing, it minimizes alloimmunization risks in multi-transfused patients. Adoption is increasing in oncology, sickle cell disease, and thalassemia care, where repeated transfusions demand highly accurate antigen-level matching for improved clinical safety outcomes.
01 Increasing Demand for Patient-specific Antibody Identification and Emergence & Re-emergence of Infectious Threats Drives MarketA key blood transfusion diagnostics market driver is the rising demand for extended antibody identification in patients receiving repeated transfusions, especially in thalassemia, sickle cell disease, and oncology cases. Hospitals increasingly use advanced immunohematology panels to detect rare and clinically significant alloantibodies before transfusion. This reduces delayed hemolytic transfusion reactions and improves compatibility matching. Increasing chronic transfusion dependency in pediatric and hematology wards is pushing adoption of automated antibody screening platforms and molecular confirmation workflows across tertiary care centers.The emergence and continuous re-emergence of infectious threats beyond traditional transfusion-transmissible infections such as HIV, HBV, and HCV is significantly strengthening demand in the blood transfusion diagnostics market. Arboviruses like West Nile virus, Zika virus, and other regionally expanding mosquito-borne infections are increasing the need for seasonal and routine nucleic acid testing due to high rates of asymptomatic viremia among donors. At the same time, climate and ecological shifts are broadening the geographic spread of pathogens, including malaria resurgence and other protozoal risks, necessitating more geographically adaptive screening protocols. Even non-classical blood-borne agents such as hantavirus are gaining attention due to their severe systemic infection profile and potential transient viremia, while norovirus, though primarily non-bloodborne, is being considered in outbreak-driven donor deferral and broader metagenomic surveillance frameworks, especially for immunocompromised recipients. Collectively, these evolving risks are expanding mandatory and precautionary screening panels, increasing reagent complexity, and driving sustained demand for multiplex, high-sensitivity, and pathogen-agnostic diagnostic platforms.
01 Fragmented Blood Traceability Systems and Limited Availability of Rare Blood Group Donor Registries Restrain Blood Transfusion Diagnostics MarketFragmented blood traceability systems act as a major blood transfusion diagnostics market restraint because many hospitals and blood banks still use disconnected or manual record-keeping methods. Lack of unified digital tracking from donor collection to transfusion creates gaps in visibility and increases the risk of errors, mismatches, and wastage of blood units. In many developing regions, limited interoperability between hospital information systems and blood bank software slows real-time tracking, reducing efficiency and affecting overall transfusion safety and inventory management.The limited scale and poor geographic coverage of rare blood group donor registries pose another restraint for the blood transfusion diagnostics market. Patients with uncommon phenotypes, such as Bombay blood group or multiple alloantibodies, often face delays in finding compatible units. Many countries lack centralized, well-updated donor databases linked with molecular typing systems, making cross-border matching slow and inefficient. This shortage increases dependence on ad-hoc searches and manual coordination, which delays emergency transfusions and reduces the effectiveness of advanced compatibility testing infrastructure in critical care situations.
01 Growth of National Rare Donor Mapping Programs and Metagenomic Sequencing Offer Unique Growth Opportunities for Market PlayersNational rare donor mapping programs are creating strong opportunities for the blood transfusion diagnostics market growth by building centralized databases of uncommon blood group phenotypes identified through molecular typing. These systems help quickly locate compatible donors for patients with rare types like Rh null or Bombay blood group. For example, India’s Rare Donor Registry under the Red Cross network and the American Rare Donor Program in the US support rapid cross-matching. This reduces transfusion delays and improves survival outcomes in complex emergency and chronic cases.Metagenomic sequencing as a universal blood safety layer creates a high-value, platform-level opportunity that is not limited to a single device type or assay, but spans multiple stakeholder groups across the transfusion ecosystem. It is particularly relevant for next-generation diagnostic companies and sequencing platform providers (such as Illumina and Oxford Nanopore-type ecosystems), blood safety solution developers, and large in vitro diagnostics firms that are already positioned in NAT and immunohematology but are looking to expand into pathogen-agnostic screening. It also opens strong opportunities for reference blood centers, national transfusion services, and large hospital networks that handle high-risk transfusions (oncology, transplant, trauma), where “unknown pathogen detection” and enhanced biosurveillance are increasingly valued. Public health agencies and government blood safety programs represent a key adoption layer, as metagenomic sequencing aligns with national-level infectious disease surveillance and pandemic preparedness frameworks.
In April 2026, ESIC issued an Expression of Interest (EOI) for the supply and management of blood bank facilities, including blood components and transfusion services under a fixed contract model.
In January 2025, Terumo signed a strategic MoU with the Shandong Institute of Medical Devices & Pharmaceutical Packaging Inspection to strengthen the medical device innovation pipeline for transfusion systems.